189 related articles for article (PubMed ID: 7663660)
21. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Eisenberg JD; Aitken ML; Dorkin HL; Harwood IR; Ramsey BW; Schidlow DV; Wilmott RW; Wohl ME; Fuchs HJ; Christiansen DH; Smith AL
J Pediatr; 1997 Jul; 131(1 Pt 1):118-24. PubMed ID: 9255202
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
[TBL] [Abstract][Full Text] [Related]
23. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
Suri R; Metcalfe C; Wallis C; Bush A
Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
[TBL] [Abstract][Full Text] [Related]
24. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.
Nasr SZ; Kuhns LR; Brown RW; Hurwitz ME; Sanders GM; Strouse PJ
Pediatr Pulmonol; 2001 May; 31(5):377-82. PubMed ID: 11340684
[TBL] [Abstract][Full Text] [Related]
25. Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis.
Milla CE
Thorax; 1998 Dec; 53(12):1014-7. PubMed ID: 10195070
[TBL] [Abstract][Full Text] [Related]
26. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
[TBL] [Abstract][Full Text] [Related]
27. [New pharmacological approaches: rhDNase].
Tournier G; Sardet A; Grosskopf C; Baculard A; Delaisi B
Rev Pneumol Clin; 1995; 51(3):193-200. PubMed ID: 7569583
[TBL] [Abstract][Full Text] [Related]
28. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis.
Shah PL; Scott SF; Geddes DM; Hodson ME
Respir Med; 1995 Aug; 89(7):499-502. PubMed ID: 7480980
[TBL] [Abstract][Full Text] [Related]
29. Where we are now with rhDNase.
Geddes DM; Shah PL
Lancet; 1999 May; 353(9166):1727. PubMed ID: 10347981
[No Abstract] [Full Text] [Related]
30. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
31. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
[TBL] [Abstract][Full Text] [Related]
32. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
Henry RL; Gibson PG; Carty K; Cai Y; Francis JL
Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
[TBL] [Abstract][Full Text] [Related]
33. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
34. New treatment strategies in cystic fibrosis: rhDNase.
Shah PL; Hodson ME
Monaldi Arch Chest Dis; 1996 Apr; 51(2):125-9. PubMed ID: 8680379
[TBL] [Abstract][Full Text] [Related]
35. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human deoxyribonuclease for cystic fibrosis.
Jones AP; Wallis CE
Cochrane Database Syst Rev; 2003; (3):CD001127. PubMed ID: 12917899
[TBL] [Abstract][Full Text] [Related]
37. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
Tarrant BJ; Le Maitre C; Romero L; Steward R; Button BM; Thompson BR; Holland AE
Respirology; 2017 Aug; 22(6):1084-1092. PubMed ID: 28397992
[TBL] [Abstract][Full Text] [Related]
38. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.
O'Donnell AE; Barker AF; Ilowite JS; Fick RB
Chest; 1998 May; 113(5):1329-34. PubMed ID: 9596315
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.
Aitken ML; Burke W; McDonald G; Shak S; Montgomery AB; Smith A
JAMA; 1992 Apr; 267(14):1947-51. PubMed ID: 1548827
[TBL] [Abstract][Full Text] [Related]
40. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
